Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

NCT05717764 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: Mitoxantrone hydrochloride liposome injection
DRUG: Capecitabine

Sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.